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Abstract
Background Higher, but also lower resting heart rate (HR), has been associated with increased cardiovascular events and 
mortality. Little is known about the interplay between HR, cardiovascular risk factors, concomitant diseases, vascular 
(endothelial) function, neurohormonal biomarkers, and all-cause mortality in the general population. Thus, we aimed to 
investigate these relationships in a population-based cohort.
Methods 15,010 individuals (aged 35–74 at enrolment in 2007–2012) from the Gutenberg Health Study were analyzed. 
Multivariable regression modeling was used to assess the relation between the variables and conditional density plots were 
generated for cardiovascular risk factors, diseases, and mortality to show their dependence on HR.
Results There were 714 deaths in the total sample at 7.67 ± 1.68 years of follow-up. The prevalence of diabetes mellitus, 
arterial hypertension, coronary and peripheral artery disease, chronic heart failure, and previous myocardial infarction 
exhibited a J-shaped association with HR. Mortality showed a similar relation with a nadir of 64 beats per minute (bpm) 
in the total sample. Each 10 bpm HR reduction in HR < 64 subjects was independently associated with increased mortality 
(Hazard Ratio 1.36; 95% confidence interval 1.06–1.75). This increased risk was also present in HR > 64 subjects (Hazard 
Ratio 1.29; 95% confidence interval 1.19–1.41 per 10 bpm increase in HR). Results found for vascular and neurohormonal 
biomarkers exhibited a differential picture in subjects with a HR below and above the nadir.
Discussion These results indicate that in addition to a higher HR, a lower HR is associated with increased mortality.
Keywords Heart rate · Mortality · Vascular (endothelial) function · Neurohumoral biomarkers · Population-based
Background
For many years, increased heart rate (HR) has been demon-
strated to be associated with increased cardiovascular (CV) 
mortality in patients with coronary artery disease (CAD) 
[1] and with chronic heart failure (CHF) [2]. Data from 
the Framingham Heart Study also suggest that mortality 
rates increase progressively in relation to HR [3]. This rela-
tion persisted after excluding individuals with pre-existing 
CV disease [3], suggesting HR was not simply a marker 
of previous cardiac damage. Conversely, pharmacological 
HR reduction with agents such as the  If-channel inhibitor, 
ivabradine, has been shown to reduce angina symptoms in 
patients with CAD [4] and to improve both congestive symp-
toms as well as prognosis in patients with CHF [5].
Based on this literature, it has been proposed that an ele-
vated HR may be considered an independent CV risk factor 
[6]. This notion must be tempered by evidence that tradi-
tional risk factors such as smoking, obesity, arterial hyper-
tension, and diabetes mellitus or prevalent CV disease such 
as CHF with reduced or preserved ejection fraction have 
also been linked to elevated HR [7, 8]. Nevertheless, HR 
reduction strategies have gained traction when associated 
with favorable outcomes as demonstrated by the inclusion 
of ivabradine in the European Society of Cardiology Treat-
ment Guidelines for CAD and CHF [9, 10]. In contrast to 
the literature outlined above, recent studies in CAD patients 
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have called into question the benefits of pharmacologic HR 
reduction with compounds such as ivabradine. Indeed, the 
 SIGNIfY study, that treated CAD patients with ivabradine 
(7.5 mg bid) reported an increase in CV events (HR of 
60.7 beats per minute (bpm) in the ivabradine group versus 
70.6 bpm in the placebo group) [11].
These conflicting data with ivabradine question whether 
the specific extent of HR reduction is important in deter-
mining benefit versus harm. Thus, we sought to address this 
question in the Gutenberg Health Study (GHS), a prospec-
tive cohort study of 15,010 individuals, subjected to intense 
characterization of both clinical and emerging functional 
CV risk factors.
Methods
Study design and sample
The GHS is a population-based, prospective single-center 
cohort study in Midwestern Germany with a total sample 
size of 15,010 individuals. The study design has been pub-
lished elsewhere in detail [12]. Briefly, individuals between 
the ages of 35 and 74 years were drawn randomly from local 
governmental registries with a sampling procedure that was 
stratified for sex, residential area (urban versus rural), and 
decades of age. Participant recruitment began in April 2007 
and was completed in April 2012. The baseline investigation 
involved a highly standardized 5-h clinical examination at 
the study center performed by specifically trained and cer-
tified medical technical assistants according to a uniform 
written protocol. Informed consent was obtained from all 
individual participants included in the study and all proce-
dures performed in the GHS were approved by the ethics 
committee of the Statutory Physician Board of the State of 
Rhineland-Palatinate and the local data safety commission-
ers. The study design is in accordance with the revised Hel-
sinki protocol and principles outlined in recommendations 
for Good Clinical and Epidemiological Practice.
Heart rate assessment
Resting HR was measured by an oscillometric technique 
(using OMRON HEM model 705IT, OMRON Medizintech-
nik, Germany) under standardized conditions. Specifically, 
measurements were performed in a quiet environment in the 
sitting position with uncrossed legs and open eyes after 5, 8, 
and 11 min of rest while remaining quiet. The mean of the 
2nd and 3rd measurements was used as the resting HR. In 
cases of atrial fibrillation (AF), results were compared with 
those determined automatically via a 12-lead resting ECG 
(GE Healthcare, CardioSoft v6). ECG-based diagnosis of 
AF was made by two cardiologists. We observed a close 
correlation in the total sample (r = 0.79) and in cases of AF 
(r = 0.76) between the two methods (Online Resource 1).
Definitions of cardiovascular risk factors 
and laboratory methods
Comprehensive information on CV risk factors was gathered 
by means of standardized interviews, anthropometric meas-
ures, and laboratory assessments. Concomitant disease and 
medication history were derived from a standardized inter-
view and from medical records. Venous blood was obtained 
after an overnight fast (at least 8 h) before vascular function 
measurement. Samples were processed for plasma and stored 
in aliquots at − 80 °C immediately after blood draw. We used 
routine laboratory methods for blood glucose and lipid meas-
urements. Plasma CT-proAVP, MR-proADM, MR-proANP, 
endothelin-1, and serum NT-proBNP and troponin I were 
determined using commercially available assays according 
to the manufacturer’s instructions as reported previously 
[13]. Reproducibility was good, with all of the coefficients of 
variation (intraassay and interassay) < 5%. The definitions of 
CV risk factors and biomarker measurements are described 
elsewhere in detail [13–16].
Determination of vascular (endothelial) function 
by flow‑mediated dilation and peripheral arterial 
tonometry
FMD of the brachial artery was measured after a 5-min 
upper arm occlusion as percentage increase of brachial 
artery diameter in resting condition according to guidelines 
as described [13, 17]. Brachial artery two-dimensional high-
resolution ultrasound images were acquired with a Philips 
HD11XE CV ultrasound machine (Best, The Netherlands) 
using a L12-5 (38  mm) linear array broadband probe. 
Artery diameters were measured offline using the commer-
cially available Brachial Analyzer software tool, version 5.0 
(Medical Imaging Applications LLC, Iowa City, IA, USA).
Regarding peripheral arterial tonometry, pneumatic pulse 
amplitude was measured with the Endo-PAT2000 device 
(Itamar Medical, Caesarea, Israel) and digital volume pulse 
was registered electronically with a PulseTrace 2000 device 
(Micro Medical Limited, Rochester, United Kingdom) 
analyzing waveform automatically as described [13, 15, 
17]. Therefore, resistance artery endothelial function was 
estimated by reactive hyperemia index (RHI), small artery 
vascular tone by reflection index (RI), and systemic large 
artery stiffness as stiffness index (SI) as well as augmenta-
tion index (AI).
Measurements of FMD and peripheral arterial tonometry 
were performed simultaneously and further details and qual-
ity control data about the good reproducibility of the meth-
ods in the GHS have been described previously [13, 15, 17].
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Data management and statistical analysis
All data of the present investigation underwent quality con-
trol by a central data management unit. Data were reviewed 
for completeness by predefined algorithms and plausibility 
criteria. Mortality updates were performed by quarterly que-
ries to the registry offices and the mortality registry Rhine-
land-Palatinate. For death reviews official death certificates 
were acquired.
Study sample characteristics are presented by 1-standard 
deviation (SD) (11 bpm) below and above the nadir of HR 
(as subsequent analyses showed the lowest mortality at a 
resting HR of 64 bpm) as absolute and relative frequency for 
categorical variables and as mean value and SD or median 
with 25th and 75th percentiles for continuous variables. 
Conditional density plots were generated for CV risk fac-
tors, concomitant CV diseases, and mortality to show their 
relative frequencies in dependence on HR. To assess the 
associations between HR, CV risk factors, CV diseases, 
and markers of subclinical disease, linear regression mod-
els with multivariable adjustment were used. All models 
are presented with the adjusted variables. Medications were 
screened as three-digit categories of the Anatomical Thera-
peutic Chemical Classification (ATC) [18] in a linear regres-
sion model for HR with adjustment for age and sex. Medica-
tion classes associated with a P value < 0.01 were taken in 
the regression models as relevant confounders. For mortality 
analyses, Cox proportional hazards regression models were 
used. All effect estimates are given with 95% confidence 
interval (95% CI) and P value. Because of the explorative 
nature of the study, no Bonferroni correction of P values 
was conducted. P values should be treated as a continuous 
measure of statistical strength of an association and they 
are, therefore, reported exactly. All tests were two sided and 
P values < 0.05 were considered significant. Statistical data 
analyses were performed using the software program R, ver-
sion 3.3.1 (http://www.R-proje ct.org).
Results
Relation between heart rate and sample 
characteristics
As evident in Table 1, with increasing HR there was a trend 
to a higher proportion of women. Most traditional CV risk 
factors showed two maxima below and above the nadir of 
HR, except obesity and smoking that exhibited a continual 
increase with higher HR. This was also true for CV diseases, 
except CAD and myocardial infarction (MI), which were 
continuously less frequent with higher HR.
To visualize the relation between HR and prevalence of 
CV risk factors (Online Resource 2) and diseases (Online 
Resource 3), conditional density plots were generated for 
the prevalence of each variable over the HR range. We 
found diabetes mellitus and arterial hypertension exhibited 
a J-shaped curve with the highest proportions in individu-
als with higher HR. In contrast, there was a steady increase 
in prevalence of obesity with increasing HR (starting from 
55 bpm). No clear pattern was found for smoking, but also 
dyslipidemia and family history of MI. Regarding concomi-
tant CV disease, subjects with CHF and peripheral artery 
disease (PAD) again showed a J-shaped curve. Individuals 
with CAD and MI had the greatest disease prevalence with 
decreased HR. For subjects with AF and stroke, no strong 
fluctuation was observed with varying HR.
Age‑ and sex‑specific distribution of heart rate 
in the population
We observed no resting HR age dependency for either sex 
in the total sample with a mean HR of 68 bpm for men and 
70 bpm for women (Online Resource 4). These characteris-
tics were also present in the subsample of individuals with-
out intake of medications. In the subsample of individuals 
with healthy status, there was a difference in HR between 
males and females with a mean HR of 65 bpm in men and 
69 bpm in women, and lower HR in men over all percentiles.
Heart rate and all‑cause mortality
Overall, there were 714 deaths in the study sample during a 
mean follow-up period of 7.67 ± 1.68 years. The conditional 
density plot showed a U-shaped relation between HR and 
all-cause mortality in the total sample (Fig. 1) with the low-
est mortality rate at a HR of 64 bpm. This relation was also 
present in an attenuated manner in the subsamples with CV 
and without CV diseases with the lowest mortality rate at 
a HR of 58 bpm and 59 bpm, respectively. The subsample 
of individuals without intake of medications had an almost 
steady increase in mortality rates with higher HR and the 
lowest mortality rate at a HR of 55 bpm.
To evaluate how the prevalence of CV risk factors and 
concomitant diseases might influence the observations, we 
decided to analyze separately multivariable models below 
and above the nadir of HR representing the minimum of 
mortality (at 64 bpm) in the population sample. As indi-
cated, there was a U-shaped relationship between HR and 
all-cause mortality with the lowest observed mortality rate at 
a nadir of 64 bpm. In preliminary analyses, 12 ATC medica-
tion classes were significantly associated with HR, so they 
were added to the multivariable models (Online Resource 5). 
In Cox regression analyses modeling for death with adjust-
ment for age, sex, CV risk factors, concomitant diseases, 
and HR-associated medication, a HR below the nadir of 
64 bpm was associated with a 36% increased risk of death 
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Table 1  Sample characteristics 
according to groups of heart 
rate
Plus–minus values are means ± standard deviation and two values in parentheses are medians with 25th and 
75th percentiles
CHF chronic heart failure, CAD coronary artery disease, MI myocardial infarction, AF atrial fibrillation, 
PAD peripheral artery disease, COPD chronic obstructive pulmonary disease, CKD chronic kidney disease, 
BMI body mass index, SBP systolic blood pressure, DBP diastolic blood pressure, MAP mean arterial pres-
sure, LDL low-density lipoprotein, HDL high-density lipoprotein, FMD flow-mediated dilation, SI stiffness 
index, RI reflection index, AI augmentation index, RHI reactive hyperemia index
*Biomarkers were available in N = 5,000
Groups of heart rate at rest
Heart rate [bpm] < 53 53–75 > 75
N 720 10,327 3,878
Sex (Women) 32.1% (231) 49.1% (5068) 53.0% (2054)
Age (years) 56.9 ± 11.1 54.9 ± 11.1 54.7 ± 11.1
Cardiovascular risk factors
Diabetes mellitus 8.6% (62) 8.0% (822) 12.9% (499)
Arterial hypertension 53.1% (382) 46.5% (4799) 57.6% (2234)
Smoking 17.8% (128) 19.3% (1993) 20.1% (779)
Obesity 22.6% (163) 22.8% (2350) 32.1% (1243)
Dyslipidemia 48.7% (350) 43.2% (4449) 46.4% (1791)
Family history of MI/stroke 23.6% (170) 22.0% (2272) 22.2% (860)
Concomitant disease
CHF 9.2% (66) 7.0% (720) 9.3% (359)
CAD 9.6% (68) 4.5% (461) 2.8% (107)
MI 6.1% (44) 3.0% (310) 2.1% (83)
Stroke 2.1% (15) 1.8% (187) 1.9% (74)
AF 18.5% (133) 16.5% (1699) 16.6% (643)
PAD 4.4% (31) 3.1% (315) 4.0% (153)
COPD 3.3% (24) 4.7% (481) 6.1% (238)
CKD 0.8% (6) 1.0% (102) 1.1% (43)
Surrogate marker for cardiovascular disease
Heart rate [bpm] 49.2 ± 3.0 65.1 ± 5.9 82.9 ± 7.2
BMI (kg/m2) 27.2 ± 4.3 27.1 ± 4.7 28.1 ± 5.6
SBP (mmHg) 131.3 ± 17.4 130.4 ± 17.2 134.8 ± 17.7
DBP (mmHg) 77.7 ± 8.7 81.5 ± 9.1 86.2 ± 9.6
MAP (mmHg) 95.6 ± 10.2 97.8 ± 10.8 102.4 ± 11.4
HbA1c (%) 5.57 ± 0.56 5.54 ± 0.65 5.67 ± 0.82
LDL (mg/dl) 132.7 ± 33.5 138.8 ± 35.2 140.6 ± 36.4
HDL (mg/dl) 55.9 ± 14.9 57.7 ± 15.6 56.7 ± 15.8
Triglycerides (mg/dl) 122.6 ± 65.8 120.2 ± 71.4 133.7 ± 98.1
FMD (%) 7.09 ± 4.44 8.18 ± 5.19 8.30 ± 5.54
Baseline brachial artery diameter 4.57 ± 0.82 4.32 ± 0.85 4.28 ± 0.86
SI (m/s) 7.30 ± 2.36 7.53 ± 2.26 7.63 ± 2.03
RI 74.72 ± 15.89 67.10 ± 15.42 58.80 ± 15.64
AI (%) 31.37 ± 25.13 19.30 ± 20.70 9.53 ± 15.69
RHI 0.62 ± 0.42 0.65 ± 0.42 0.65 ± 0.41
Baseline pulse amplitude 620.2 ± 471.0 568.3 ± 444.9 546.6 ± 407.0
Troponin I > 0.02* (ng/mL) 6.9% (18) 3.2% (106) 4.5% (57)
Endothelin 1* (pmol/l) 59.4 (50.9/68.3) 58.9 (50.2/67.7) 59.3 (51.0/69.2)
CT-proAVP* (pmol/l) 2.75 (1.75/4.25) 2.73 (1.79/4.31) 2.96 (1.79/4.84)
MR-proADM* (nmol/L) 0.47 (0.40/0.56) 0.46 (0.39/0.53) 0.47 (0.40/0.57)
NT-proBNP* (pg/mL) 86.47 (39.88/192.43) 62.44 (29.48/125.57) 55.95 (24.06/109.96)
MR-proANP* (pmol/l) 89.2 (65.8/121.0) 67.6 (50.7/91.0) 57.0 (43.1/78.6)
1317Clinical Research in Cardiology (2019) 108:1313–1323 
1 3
per 10 bpm decrease, while a HR above 64 bpm was associ-
ated with a 30% increased risk of death per 10 bpm increase 
(Table 2).
Cardiovascular risk correlates of heart rate
To assess clinically relevant CV risk correlates of HR, we 
used linear regression analyses modeling for HR (Fig. 2). 
Focusing on HR below the nadir (≤ 64 bpm), multivariable 
models indicated, lower age and female sex were indepen-
dently associated with HR. Analyses of individuals with 
HR above 64 bpm revealed lower age, female sex, higher 
body-mass-index, diabetes mellitus, and arterial hyperten-
sion were independently associated with HR.
Total sample Subsample with cardiovascular disease
Subsample without cardiovascular disease Subsample without intake of medication
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Fig. 1  Conditional density plots presenting the relation between heart 
rate in beats per minute and mortality rate in % in the total and sub-
samples. Black stripes indicate death events and red lines indicate 
lowest mortality rate in relation to heart rate for a 64, b 58, c 59, and 
d 55. Sample sizes and number of deaths were for a N = 14,925 and 
714 deaths, b N = 1432 and 214 deaths, c N = 13,233 and 471 deaths, 
and d N = 3517 and 82 deaths
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Heart rate and subclinical markers of cardiovascular 
disease
To further elucidate relations of subclinical markers of CV 
disease with HR, linear regression analyses modeling for HR 
with adjustment for age, sex, CV risk factors, concomitant 
diseases, and HR-associated medication were used (Table 3). 
Troponin I, CT-proAVP, NT-proBNP, and MR-proANP were 
independently associated with a HR of 1-SD below the nadir 
(< 53 bpm). CT-proAVP, MR-proADM, NT-proBNP, and 
MR-proANP were independently associated with a HR of 
1-SD above the nadir (> 75 bpm).
Regarding vascular function markers, FMD (borderline 
significant p = 0.050), RI, AI, and SI were independently 
associated with a HR below 53 bpm. These parameters 
were also independently associated with a HR above 75 
Table 2  Heart rate as an independent predictor for all-cause mortality
Hazard ratios and 95% confidence intervals were derived from a Cox proportional hazard regression model. Death from all causes was the 
dependent variable and heart rate (modeled per 10 beats per minute) the independent variable. There were 714 deaths at follow-up in the total 
sample
Cardiovascular risk factors comprise arterial hypertension, diabetes mellitus, dyslipidemia, family history of myocardial infarction or stroke, 
obesity, and smoking
Concomitant diseases were atrial fibrillation, chronic heart failure, coronary artery disease, myocardial infarction, stroke, peripheral artery dis-
ease, chronic obstructive pulmonary disease, and chronic kidney disease
Medication includes 12 medication classes from ATC taken at the time of examination, which were associated with heart rate (see Online 
Resource 5)
Adjustment for age and sex Additional adjustment for cardiovas-
cular risk factors and concomitant 
diseases
Additional adjustment for 
medication
Hazard ratio per 
10 bpm (95% CI)
P value Hazard Ratio per 
10 bpm (95% CI)
P value Hazard ratio per 
10 bpm (95% CI)
P value
Heart rate below 64 bpm 1.54 (1.22; 1.95) 0.00029 1.44 (1.12; 1.85) 0.0039 1.36 (1.06; 1.76) 0.016
Heart rate above 64 bpm 1.35 (1.25; 1.46) < 0.0001 1.30 (1.20; 1.41) < 0.0001 1.30 (1.19; 1.41) < 0.0001
(a) Heart rates ≤64 beats per minute
Sex (Women)
Age [10y]
BMI [5kg/m²]
Diabetes
Hypertension
Smoking
Dyslipidemia
FH of MI/stroke
Beta Estimate
B [95%CI] p−value
Crude Adjusted
1.05 [0.79; 1.31]
−0.25 [−0.36; −0.13]
−0.08 [−0.22; 0.07]
−0.40 [−0.87; 0.08]
−0.45 [−0.71; −0.19]
0.14 [−0.19; 0.48]
−0.43 [−0.69; −0.17]
−0.20 [−0.51; 0.11]
1.04 [0.78; 1.31]
−0.19 [−0.33; −0.06]
0.09 [−0.07; 0.25]
−0.07 [−0.57; 0.42]
−0.21 [−0.52; 0.09]
0.04 [−0.29; 0.38]
−0.09 [−0.38; 0.20]
−0.24 [−0.55; 0.07]
<0.0001
<0.0001
0.31
0.10
0.00063
0.39
0.0012
0.22
<0.0001
0.0049
0.26
0.78
0.17
0.80
0.53
0.14
−0.8 −0.4 0.0 0.4 0.8 1.2 1.6
Sex (Women)
Age [10y]
BMI [5kg/m²]
Diabetes
Hypertension
Smoking
Dyslipidemia
FH of MI/stroke
Beta Estimate
B [95%CI] p−value
Crude Adjusted
0.24 [−0.09; 0.58]
0.24 [0.08; 0.39]
0.77 [0.61; 0.93]
2.62 [2.06; 3.17]
2.42 [2.09; 2.75]
−0.09 [−0.50; 0.33]
0.85 [0.52; 1.19]
0.05 [−0.35; 0.45]
0.81 [0.47; 1.15]
−0.33 [−0.49; −0.16]
0.37 [0.19; 0.54]
1.89 [1.30; 2.47]
2.35 [1.98; 2.73]
0.19 [−0.23; 0.61]
0.28 [−0.08; 0.64]
−0.31 [−0.71; 0.09]
0.15
0.0022
<0.0001
<0.0001
<0.0001
0.68
<0.0001
0.79
<0.0001
0.00012
<0.0001
<0.0001
<0.0001
0.37
0.12
0.13
−1 0 1 2 3
(b)  Heart rates >64 beats per minute 
Fig. 2  Correlates of heart rate. Beta estimates with 95% confidence 
intervals were derived from a linear regression model modeling for 
heart rates a ≤ 64 and b > 64 beats per minute as dependent variable 
and cardiovascular risk factors as independent variables. The crude 
model denotes a univariate model (white) and the adjusted model 
(black) denotes a multivariable model including all listed variables as 
covariates
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Table 3  Heart rate and relation with subclinical markers of cardiovascular disease for (1) humoral and (2) vascular biomarkers
Beta estimates and 95% confidence intervals were derived from a linear regression model modeling for heart rates below 53 (versus above 53) 
and above 75 (versus below 75) beats per minute (dependent variables) and with biomarkers as independent variables
Cardiovascular risk factors comprise arterial hypertension, diabetes mellitus, dyslipidemia, family history of myocardial infarction or stroke, 
obesity, and smoking
Concomitant diseases were atrial fibrillation, chronic heart failure, coronary artery disease, myocardial infarction, stroke, peripheral artery dis-
ease, chronic obstructive pulmonary disease, and chronic kidney disease
Medication includes 12 medication classes from ATC taken at the time of examination, which were associated with heart rate (see Online 
Resource 5)
Adjusted for age and sex
Beta estimate (95% CI)
P value Additionally adjusted for 
cardiovascular risk factors 
and concomitant diseases
Beta estimate (95% CI)
P value Additionally adjusted for 
medication
Beta estimate (95% CI)
P value
(1) Humoral biomarkers
Heart rates < 53 bpm
Troponin I 0.21 (0.12; 0.30) < 0.0001 0.19 (0.10; 0.28) < 0.0001 0.20 (0.11; 0.29) < 0.0001
Endothelin 1 − 0.013 (− 0.040; 0.015) 0.37 − 0.0088 (− 0.036; 0.018) 0.53 − 0.020 (− 0.048; 0.0071) 0.15
CT-proAVP − 0.14 (− 0.23; − 0.059) 0.00097 − 0.14 (− 0.22; − 0.048) 0.0023 − 0.15 (− 0.23; − 0.058) 0.0012
MR-proADM 0.0086 (− 0.020; 0.037) 0.55 0.024 (− 0.0017; 0.050) 0.067 0.0078 (− 0.018; 0.034) 0.55
NT-proBNP 0.44 (0.30; 0.58) < 0.0001 0.39 (0.25; 0.53) < 0.0001 0.24 (0.11; 0.38) 0.00055
MR-proANP 0.32 (0.27; 0.37) < 0.0001 0.30 (0.25; 0.35) < 0.0001 0.22 (0.17; 0.27) < 0.0001
Heart rates > 75 bpm
Troponin I − 0.023 (− 0.068; 0.022) 0.31 − 0.038 (− 0.084; 0.0075) 0.10 − 0.039 (− 0.086; 0.0073) 0.098
Endothelin 1 0.020 (0.0064; 0.034) 0.0043 0.0097 (− 0.0044; 0.024) 0.18 0.014 (− 0.00037; 0.028) 0.056
CT-proAVP 0.14 (0.092; 0.18) < 0.0001 0.10 (0.059; 0.15) < 0.0001 0.11 (0.069; 0.16) < 0.0001
MR-proADM 0.035 (0.021; 0.050) < 0.0001 0.0086 (− 0.0048; 0.022) 0.21 0.016 (0.0025; 0.029) 0.020
NT-proBNP − 0.21 (− 0.28; − 0.14) < 0.0001 − 0.21 (− 0.28; − 0.14) < 0.0001 − 0.13 (− 0.20; − 0.056) 0.00047
MR-proANP − 0.18 (− 0.20; − 0.15) < 0.0001 − 0.17 (− 0.20; − 0.15) < 0.0001 − 0.13 (− 0.16; − 0.11) < 0.0001
(2) Vascular biomarkers
Heart rates < 53 bpm
Flow-mediated dilation − 0.34 (− 0.74; 0.059) 0.095 − 0.42 (− 0.82; − 0.015) 0.042 − 0.41 (− 0.81; 0.00075) 0.050
Baseline brachial artery 
diameter
0.0086 (− 0.038; 0.055) 0.71 0.023 (− 0.022; 0.068) 0.31 0.029 (− 0.017; 0.074) 0.22
Reactive hyperemia index 0.030 (− 0.0036; 0.064) 0.080 0.018 (− 0.015; 0.051) 0.30 0.026 (− 0.0075; 0.059) 0.013
Baseline pulse amplitude − 17.4 (− 51.6; 16.7) 0.32 − 4.79 (− 38.2; 28.6) 0.78 − 6.34 (− 40.1; 27.5) 0.71
Reflection index 7.49 (6.32; 8.67) < 0.0001 7.40 (6.21; 8.59) < 0.0001 7.45 (6.24; 8.66) < 0.0001
Augmentation index 15.9 (14.4; 17.4) < 0.0001 15.5 (14.0; 16.9) < 0.0001 15.2 (13.7; 16.7) < 0.0001
Stiffness index − 0.67 (− 0.83; − 0.51) < 0.0001 − 0.65 (− 0.82; − 0.49) < 0.0001 − 0.58 (− 0.74; − 0.41) < 0.0001
Heart rates > 75 bpm
Flow-mediated dilation − 0.012 (− 0.21; 0.18) 0.90 0.19 (− 0.0058; 0.39) 0.057 0.22 (0.017; 0.42) 0.033
Baseline brachial artery 
diameter
0.048 (− 0.018; 0.027) 0.68 − 0.037 (− 0.060; − 0.015) 0.00097 − 0.043 (− 0.065; − 0.020) 0.00023
Reactive hyperemia index − 0.020 (− 0.036; − 
0.0030)
0.021 − 0.00012 (− 0.017; 0.016) 0.99 − 0.0038 (− 0.021; 0.013) 0.65
Baseline pulse amplitude − 7.27 (− 24.1; 9.58) 0.40 − 26.2 (− 42.8; − 9.63) 0.0020 − 26.2 (− 43.1; − 9.31) 0.0024
Reflection index − 8.15 (− 8.70; − 7.59) 0.11 − 8.34 (− 8.91; − 7.77) < 0.0001 − 8.48 (− 9.06; − 7.90) < 0.0001
Augmentation index − 11.1 (− 11.8; − 10. 3) < 0.0001 − 10.9 (− 11.7; − 10.2) < 0.0001 − 10.8 (− 11.6; − 10.1) < 0.0001
Stiffness index 0.23 (0.15; 0.31) < 0.0001 0.17 (0.090; 0.25) < 0.0001 0.12 (0.044; 0.20) 0.0023
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bpm. Furthermore, the structural vessel markers, baseline 
brachial artery diameter and baseline pulse amplitude, 
were associated with a HR above 75 bpm.
Discussion
The results of the present investigation demonstrate for the 
first time that in a large population-based cohort, in addition 
to a higher HR, a lower HR is associated with increased 
all-cause mortality after adjustment for age, sex, CV risk 
factors, concomitant disease, and HR-associated medication. 
We found a J-shaped relationship between HR and concomi-
tant CV disease such as CHF, CAD, PAD, and previous MI. 
Moreover, the relations of HR with a large panel of vascu-
lar and humoral biomarkers exhibited a differential picture 
when distinguishing between a lower and higher HR.
Heart rate, cardiovascular risk factors, 
and concomitant cardiovascular disease
With the present study, we did not detect any dependency 
of age on HR in men and women, neither in the total sam-
ple, or the healthy subsample. This conflicts with previous 
observations, where a progressive decrease in HR over 
time with aging has been reported [19, 20]. As demon-
strated before, women have a HR being 3–4 bpm higher 
compared to men [3]. This difference operates at any age, 
but does not increase with age. About 5% of HR was above 
87 bpm in men and 88.5 bpm in women, and below 51.5 
in men and 54.5 in women. These values are interestingly 
around 7–9 bpm lower as shown in the Framingham Study, 
where 5% of HR were above 95 bpm and below 60 bpm 
[3]. The reasons for the quite substantial reduction of 
almost 10 bpm in our cohort may be that study subjects of 
the GHS are more physical active or that more patients in 
the GHS have been treated with HR-lowering medication 
such as beta-receptor blockers having negative chrono-
tropic effects. The observed difference in HR between men 
and women may be also explained, e.g., by a more on 
prevalence of CV risk factors [21]. Men, however, had a 
higher blood pressure over the entire HR range, were more 
likely to be smokers, obese, and diabetic. Men had higher 
triglyceride and lower high-density lipoprotein levels. The 
prevalence of subjects with previous MI, established CAD, 
and CHF was higher in men compared to women, while 
AF was more prevalent in women. In general, conditional 
density plots revealed that patients with CAD, previous 
MI, CHF, and PAD clearly had a J-shaped curve with 
highest prevalence in the lowest and highest HR groups, 
respectively.
Heart rate and relations with hemodynamic, 
vascular, and humoral biomarkers
Resting HR has been consistently demonstrated to be associ-
ated with arterial blood pressure in epidemiologic [19, 20], 
but also pathophysiological studies [22, 23]. In the general 
population, this relationship between HR and blood pressure 
was confirmed over the whole range of blood pressure values 
and has been observed at any age [22]. In the present study, 
we could observe an increase in systolic blood pressure 
1-SD below and above the nadir of HR, but also a steady 
increase in diastolic and mean arterial pressure accompanied 
by a steady increase in arterial stiffness (as indicated by SI) 
over all HR groups. These results are in line with previ-
ous observations demonstrating that, e.g., increasing HR in 
patients with implanted pacemaker will, with a higher HR, 
increase blood pressure and simultaneously increase arterial 
stiffness [24, 25].
Regarding humoral biomarkers, NT-proBNP, and MR-
proANP showed a clear decrease over the HR groups, while 
other markers did not show a clear pattern. When comparing 
groups of HR (i.e., <53 bpm and > 75 bpm) in linear regres-
sion analysis, CT-proAVP, NT-proBNP and MR-proANP 
remained independently associated in both HR groups, but 
in an inverse relation. With respect to vascular biomarkers, 
increased HR from below 55 bpm up to above 75 bpm was 
accompanied by an increase in FMD, RHI, and SI, while RI 
and AI decreased concordantly. However, linear regression 
models revealed reduced FMD and SI as well as increased 
RI and AI to be independently associated with a HR below 
53 bpm, while these markers were also independently related 
to a HR above 75 bpm, but again in an inverse relation.
The pattern of results found for humoral and vascular 
biomarkers clearly exhibited a differential picture in subjects 
with a HR below 53 bpm and above 75 bpm, suggesting that 
different pathophysiological mechanisms may be responsi-
ble for the relation of HR with mortality as indicated by 
the inverse relation of markers. The present analyses cannot 
fully clear at this point since further mechanisms may be 
involved in the interplay between HR and these markers. 
Clearly, a higher HR is directly associated with autonomic 
imbalance and thus a hyperactive sympathetic and a hypoac-
tive parasympathetic system. Nevertheless, it is still difficult 
to specify HR-mediated effects of autonomic imbalance and 
to distinguish from related effects, in particular for lower HR 
[26]. However, increased troponin I, NT-proBNP, and MR-
proANP levels as well as reduced FMD and increased RI 
and AI were independently associated with a HR below 53, 
which may demonstrate relevant pathways for understanding 
the relationship between lower HR and mortality, whereas 
the association with higher HR may be more affected by an 
increased prevalence of CV risk factors.
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Heart rate and all‑cause mortality
With the present study, we showed an increase in mortal-
ity rates with higher HR, as it has been shown before [27], 
but also an increase in mortality in patients with lower HR. 
The nadir of HR, where the lowest mortality was seen was 
64 bpm. The observation of a J-shaped mortality curve is 
contrasting previous reports from the Framingham Study 
where mortality increases progressively with resting HR [3]. 
Likewise, in the Goteborg Primary Prevention Trial [28] and 
the NHEFS Cohort [29], the rate of death from all causes 
and CV disease increased as a function of increasing HR 
or when pulse rate increased beyond 84 bpm. Since beta-
receptor blockade was in the late 80s not established yet for 
the treatment of patients with CHF, it is tempting to specu-
late that the J-shaped curve seen in the present study rather 
reflects a drug effect. However, we observed a J-shaped rela-
tion between HR and mortality in the subsample without 
CV disease and further adjusted for concomitant disease as 
well as HR-associated medication (including beta-receptor 
blockers) in Cox regression analysis for mortality.
Optimal heart rate in patients with coronary artery 
disease and chronic heart failure
Although there is no doubt that patients with CAD and 
CHF will have symptomatic and/or prognostic benefit from 
a reduction in HR being higher than 70 bpm [2, 4, 5, 11], the 
question remains whether the clinical benefit of a HR reduc-
tion may be turned into the opposite when the HR reduction, 
e.g., is too pronounced. The results of the present study sug-
gest that a HR below 64 bpm may increase rather than fur-
ther decrease mortality. These findings may explain at least 
in part why the recent  SIGNIfY Trial [11] failed to demon-
strate beneficial effects on patients with stable CAD having 
activity limiting angina and a HR higher than 70 bpm. By 
adding ivabradine to baseline beta-receptor blocker therapy, 
the patients had a quite substantial HR reduction of about 
8 bpm, but also high numbers of side effects such as symp-
tomatic bradycardia and in the subgroup of patients with 
limiting angina even more CV event rates [11]. Hereby, the 
J-shaped relationship between HR and outcomes as observed 
in the present study would be one possible explanation.
Strengths and limitations
To our knowledge, this is the first study that evaluated the 
association between higher but also lower HR and a large 
panel of markers suggestive of CV risk as well as mortality 
in a population-based setting. Strengths of the present study 
include the detailed characterization of age- and sex-spe-
cific distribution of HR in the general population. Further, 
the large sample size of the GHS cohort across a broad age 
spectrum as well as the comprehensive and standardized 
assessment of multiple biomarkers, CV risk factors, con-
comitant disease, and further included variables are notable. 
Some limitations, however, need to be considered. A major 
limitation of the present analysis is the lack of information 
on the cause of death. We cannot differentiate between CV 
and non-CV causes. However, since almost half of mor-
tality cases are due to CV causes [30], we still have good 
power to detect clinically relevant associations. Although 
the mortality data were derived from a prospective design, 
results must be considered with caution in terms of causation 
given the observational and non-randomized nature of the 
study. We cannot fully exclude, for example, that altered HR 
may be simply an epi-phenomenon, resulting from a hidden 
and unmeasured confounding etiological cause, leading to 
increased mortality. Also, we cannot differentiate between 
specific drug effects as we solely considered HR-associated 
medication by class, which may have affected our results. 
For example, it is known that HR reduction induced by 
beta-receptor blockers is complex as a result of autonomic 
modulations, while HR reduction is the only CV effect of 
ivabradine [31, 32]. Moreover, the mortality analyses were 
based on a single baseline measurement of HR and thus may 
be more sensitive to fluctuations.
Summary and conclusions
The results of the present study show a higher prevalence in 
most of CV risk factors with a higher HR. In patients with 
concomitant CV disease such as CHF, CAD, PAD, and pre-
vious MI, there is a clear J-shaped relationship with HR. In 
this population-based cohort, the all-cause mortality curve 
revealed a nadir of HR at 64 bpm with an increase in mor-
tality above but also below the nadir. The study may also 
indicate that patients with CHF may not benefit from a too 
strong HR reduction. Further studies are warranted to get 
more insight in the pathophysiological mechanisms underly-
ing the relationship between a low HR and mortality.
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